Trinity Biotech, Latch Medical announce CGM+ drug-delivery partnership

Trinity Biotech and Latch Medical have announced a strategic collaboration to integrate Trinity’s AI-native CGM+ wearable biosensor with Latch’s Pharma Latch intradermal drug-delivery platform to guide precise injectable therapies for diabetes, obesity, and other metabolic conditions, aiming to create an AI-guided metabolic health platform. Trinity also plans a strategic equity investment in Latch as part of advancing regulatory-ready, biosensor-informed treatment approaches.